Curcumin Nanoparticle Enhances the Anticancer Effect of Cisplatin by Inhibiting PI3K/AKT and JAK/STAT3 Pathway in Rat Ovarian Carcinoma Induced by DMBA

Overview

Journal Front Pharmacol

Date 2021 Feb 4

PMID 33536913

Citations 20

Authors

Ni Made Dwi Sandhiutami

Wawaimuli Arozal

Melva Louisa

Deni Rahmat

Puspita Eka Wuyung

Affiliations

Soon will be listed here.

Abstract

Cisplatin has been used for decades for the treatment of ovarian cancer. However, despite its potent anticancer effect, cisplatin's efficacy as a single agent was inadequate in patients with advanced stage. Curcumin has been shown to sensitize cisplatin activity in several cancer models. However, the low bioavailability of curcumin has limited its anticancer potential. Hence, nano-formulation of curcumin was developed to increase its therapeutic efficacy in ovarian cancer. The objective of this study was to investigate the mechanism of curcumin nanoparticles given in combination with cisplatin in rat ovarian carcinoma induced by dimethylbenz(a)anthracene (DMBA). The administration of cisplatin and nanocurcumin resulted in a significant reduction in ovarian tumor volume and weight. Furthermore, there were reduction in expressions of Ki67, TGF-β, PI3K, and Akt phosphorylation. Co-treatment of cisplatin and nanocurcumin also reduced JAK expression, STAT3 phosphorylation, and reduced IL-6 concentrations. Altogether, nanocurcumin, given as a co-treatment with cisplatin has therapeutic potential in ovarian cancer models by inhibiting proliferation through downregulation of PI3K/Akt and JAK/STAT3 signaling pathways.

Citing Articles

Curcumin-Based Nanoparticles: Advancements and Challenges in Tumor Therapy.

Wahnou H, El Kebbaj R, Liagre B, Sol V, Limami Y, Duval R Pharmaceutics. 2025; 17(1).

PMID: 39861761 PMC: 11768525. DOI: 10.3390/pharmaceutics17010114.

evaluation, characterization, and anticancer activity of curcumin-nimbin loaded nanoformulation in HCT-116 cell lines.

Madeswaran A, Tamilazhagan S, Mohan S BioTechnologia (Pozn). 2025; 105(4):355-365.

PMID: 39844869 PMC: 11748221. DOI: 10.5114/bta.2024.145256.

SUGT1 is a prognostic biomarker and is associated with immune infiltrates in ovarian cancer.

Ge L, Liu X, Zhang L, Zhang J, Song G Eur J Med Res. 2025; 30(1):21.

PMID: 39794869 PMC: 11724497. DOI: 10.1186/s40001-024-02232-5.

A nanoscale natural drug delivery system for targeted drug delivery against ovarian cancer: action mechanism, application enlightenment and future potential.

Li Y, Shen Q, Feng L, Zhang C, Jiang X, Liu F Front Immunol. 2024; 15:1427573.

PMID: 39464892 PMC: 11502327. DOI: 10.3389/fimmu.2024.1427573.

Nanocurcumin in cancer treatment: a comprehensive systematic review.

Boroughani M, Moaveni A, Hatami P, Mansoob Abasi N, Seyedoshohadaei S, Pooladi A Discov Oncol. 2024; 15(1):515.

PMID: 39349709 PMC: 11442806. DOI: 10.1007/s12672-024-01272-x.

References

Ng S, Tsao M, Nicklee T, Hedley D . Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res. 2001; 7(10):3269-75. View

Bortel N, Armeanu-Ebinger S, Schmid E, Kirchner B, Frank J, Kocher A . Effects of curcumin in pediatric epithelial liver tumors: inhibition of tumor growth and alpha-fetoprotein in vitro and in vivo involving the NFkappaB- and the beta-catenin pathways. Oncotarget. 2015; 6(38):40680-91. PMC: 4747361. DOI: 10.18632/oncotarget.5673. View

Hussain Z, Arooj M, Malik A, Hussain F, Safdar H, Khan S . Nanomedicines as emerging platform for simultaneous delivery of cancer therapeutics: new developments in overcoming drug resistance and optimizing anticancer efficacy. Artif Cells Nanomed Biotechnol. 2018; 46(sup2):1015-1024. DOI: 10.1080/21691401.2018.1478420. View

Yallapu M, Jaggi M, Chauhan S . Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today. 2011; 17(1-2):71-80. PMC: 3259195. DOI: 10.1016/j.drudis.2011.09.009. View

Grivennikov S, Karin E, Terzic J, Mucida D, Yu G, Vallabhapurapu S . IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009; 15(2):103-13. PMC: 2667107. DOI: 10.1016/j.ccr.2009.01.001. View

Liang F, Ren C, Wang J, Wang S, Yang L, Han X . The crosstalk between STAT3 and p53/RAS signaling controls cancer cell metastasis and cisplatin resistance via the Slug/MAPK/PI3K/AKT-mediated regulation of EMT and autophagy. Oncogenesis. 2019; 8(10):59. PMC: 6785561. DOI: 10.1038/s41389-019-0165-8. View

Dai L, Wang G, Pan W . Andrographolide Inhibits Proliferation and Metastasis of SGC7901 Gastric Cancer Cells. Biomed Res Int. 2017; 2017:6242103. PMC: 5286540. DOI: 10.1155/2017/6242103. View

Komiyama S, Kurahashi T, Ishikawa M, Tanaka K, Komiyama M, Mikami M . Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin. Oncol Rep. 2011; 25(4):1131-8. DOI: 10.3892/or.2011.1151. View

Yu H, Jove R . The STATs of cancer--new molecular targets come of age. Nat Rev Cancer. 2004; 4(2):97-105. DOI: 10.1038/nrc1275. View

10.

Selvendiran K, Bratasz A, Tong L, Ignarro L, Kuppusamy P . NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. Cell Cycle. 2008; 7(1):81-8. PMC: 2890223. DOI: 10.4161/cc.7.1.5103. View

11.

Prat J . FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol. 2015; 26(2):87-9. PMC: 4397237. DOI: 10.3802/jgo.2015.26.2.87. View

12.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

13.

Huang T, Deng Y, Hsu J, Leu W, Marchesi E, Capobianco M . Evaluation of the Anticancer Activity of a Bile Acid-Dihydroartemisinin Hybrid Ursodeoxycholic-Dihydroartemisinin in Hepatocellular Carcinoma Cells. Front Pharmacol. 2020; 11:599067. PMC: 7748086. DOI: 10.3389/fphar.2020.599067. View

14.

Brown K, Toker A . The phosphoinositide 3-kinase pathway and therapy resistance in cancer. F1000Prime Rep. 2015; 7:13. PMC: 4335789. DOI: 10.12703/P7-13. View

15.

Akinleye A, Avvaru P, Furqan M, Song Y, Liu D . Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol. 2013; 6(1):88. PMC: 3843585. DOI: 10.1186/1756-8722-6-88. View

16.

Alsina-Sanchis E, Figueras A, Lahiguera A, Vidal A, Casanovas O, Graupera M . The TGFβ pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels. Int J Cancer. 2016; 139(8):1894-903. DOI: 10.1002/ijc.30233. View

17.

Bose S, Banerjee S, Mondal A, Chakraborty U, Pumarol J, Croley C . Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy. Cells. 2020; 9(6). PMC: 7348822. DOI: 10.3390/cells9061451. View

18.

Yunos N, Beale P, Yu J, Huq F . Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells. Anticancer Res. 2011; 31(4):1131-40. View

19.

Park W, Amin A, Chen Z, Shin D . New perspectives of curcumin in cancer prevention. Cancer Prev Res (Phila). 2013; 6(5):387-400. PMC: 3693758. DOI: 10.1158/1940-6207.CAPR-12-0410. View

20.

Shanmugam M, Rane G, Mathi Kanchi M, Arfuso F, Chinnathambi A, Zayed M . The multifaceted role of curcumin in cancer prevention and treatment. Molecules. 2015; 20(2):2728-69. PMC: 6272781. DOI: 10.3390/molecules20022728. View